Seasonal administration of omalizumab in patients with uncontrolled asthma and sensitization to olive pollen

Serrano P1,2,3, Navas A1,2,3, Ruiz-León B1,2,3, Herrero L4, Rondón C3,5, Jurado A1,2,3, Moreno-Aguilar C1,2,3

1Department of Immunology and Allergy, Reina Sofia University Hospital, Cordoba, Spain.
2Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
3National Network ARADyAL, Carlos III Health Institute, Madrid, Spain.
4Department of Information, Computer Systems and Archives Systems (Contabilidad Analítica), Hospital Infanta Margarita, Cabra, Córdoba, Spain.
5Biomedical Research Institute of Málaga (IBIMA)/ Allergy Unit Hospital Regional Universitario de Malaga, Spain.

*All authors have made a substantial contribution to the work, drafted the work and given their final approval.

Corresponding:
Berta Ruiz León
Department of Immunology and Allergy, Reina Sofia University Hospital. Avenida Menéndez Pidal s/n. Córdoba. Spain.
E-mail: rulebe@gmail.com

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0657
Sensitization to olive pollen leads to the development of asthma. Particularly, in areas with high pollen counts, such as the south Mediterranean, sensitization to Ole e 7 involves a greater severity of asthma [1-3].

In Cordoba, olive and grasses are important sources of pollen causing rhinoconjunctivitis and asthma during the spring season. Only olive pollen reaches extreme counts (>20,000 grains/m3/year).

Allergen immunotherapy (AIT) is indicated when sensitization is clinically relevant and pharmacologic asthma control is not satisfactory. When sensitization to Ole e 7 is single or predominant AIT is associated with a higher incidence of adverse reactions [4]. Moreover, the lack of control of minor allergens in the vast majority of extracts represents an additional difficulty[5]. Therefore, for patients predominantly sensitized to Ole e 7, AIT could be unappropriated.

Omalizumab has been widely used to treat perennial allergic severe asthma [6], however, we do not know about severe asthma due to pollen sensitization. The aim of this study was to analyze the results of a pilot seasonal treatment with omalizumab, in
daily practice conditions, in patients with uncontrolled seasonal asthma, strong sensitization to minor olive allergens and exposed to high pollen counts.

Retrospective data from 33 patients (84.4% women; mean age: 31.4; SD: 12.35) were selected based on: 1) high exposure to olive pollen; 2) moderate-severe persistent asthma [7]; 3) poor control of symptoms in two previous springs according to GEMA guide [7]; 4) relevant sensitization to minor olive allergens (mean values and SD of sIgE were Ole e 1 24.5 (26.5); Ole e 7 67.5 (70.8); Ole e 9 19.5 (28.6). More data in Supplementary Fig 1); 5) having been treated off-label with omalizumab for 16 weeks (March-June 2013 including olive pollination season) under standardized clinical practice (according to the manufacturer's product data sheet) [8].

The single exclusion criterion was to be sensitized to other pollens.

Interestingly, 66% of included patients had received olive immunotherapy with poor clinical response and unacceptable rate of adverse reactions.

Clinical variables were collected from medical records: 1) daytime symptoms (dyspnea, cough, wheezing, chest tightness), activity limitation, night symptoms/awake, need for relief medication (SABA), exacerbations, maintenance medication (inhaled corticosteroids with or without LABA, antileukotriene, others); 2) severity qualitative parameters (oral corticosteroids-emergency visits).

An asthma control synthetic index (ACSI) was established based on GEMA guide [7]:

ACSI value 2 (well controlled asthma): absence of night symptoms, activity limitations, exacerbations, daytime symptoms \( \leq \) 2 days/week, need for SABA \( \leq \) 2 times/week, FEV1 \( \geq \) 80% of theoretical value.

ACSI value 1 (partially controlled asthma): At least 4 out of 6 conditions from ACSI 2.
ACSI value 0 (badly controlled asthma): Less than 4 out of 6 conditions from ACSI 2.

ACSI was monthly obtained from March to June 2013 in all patients matching with omalizumab administration visits. The worst ACSI obtained for each patient was selected to perform statistical analysis. Global spring ACSI of 2011 was obtained from medical records.

We performed a descriptive analysis of variables. Comparison were made between 2013 and 2011 (before and after omalizumab). The season of 2012 was not considered in order to avoid a possible bias due to lower pollen counts (Supplementary Fig 2). McNemar’s test was used to measure the consistency in changes of ACSI and severity parameters (oral corticosteroids-emergency visits). A bivariate independence analysis ($\chi^2$) was performed between the dependent variable (ACSI) and the independent variables, gender and age. Significance was set at $\alpha=0.05$.

The study protocol was approved by local Ethics Committee and informed consent was obtained from each patient, or their legal representative.

Omalizumab doses ranged from 150mg/4weeks to 600mg/2weeks. Most frequently dose was 450mg/2weeks (27.2% of patients). Both ACSI and severity parameters were significantly improved ($P<0.001$) after treatment with omalizumab (Table 1). Detailed data can be seen in Supplementary Fig 3. Patients from GEMA-step 6 obtained the best results (Supplementary Table 1). $\chi^2$ test showed no significant differences between ACSI and independent variables (gender: $P = 1.000$; age: $P = 0.688$).
This study showed that seasonal treatment with omalizumab in patients with uncontrolled asthma due to olive pollen allergy improves the disease control. Our patient cohort had poorly controlled asthma during olive pollination but remained mostly asymptomatic for the rest of the year. Despite this reality, guidelines do not classify seasonal asthma as perennial, depending on severity.

Asthma control is a complex health problem from the perspective of its indicators. In the present study, omalizumab had an impact on all patients with a reduced need of oral corticosteroids and fewer emergency visits. Patients suffered fewer symptoms using fewer drugs and medical interventions. Whether omalizumab further than providing a better control of asthma, has a possible preventive role in future worsening, as well as potential cost savings [9] are questions unsolved yet.

Seasonal treatment with omalizumab in pollinic patients with rhinitis was previously investigated, resulting in improvement of symptoms and quality of life, and reduced use of rescue medication [10,11].

An important aspect of this study was that patients were treated with omalizumab only for 16 weeks. Whether we had overlooked the seasonal nature of asthma and treated patients based on their severity and control criteria, we would have spent 6.708 pre-filled syringes of 150mg (2,931.328,92 €). In contrast, we only consumed 516 (225,486,84 €).

In summary, the drug administration reduction and the better control of severe pollen asthma obtained by seasonal treatment with omalizumab results appropriate cost-benefit balance regarding a perennial schedule. Healthcare systems should not ignore this protocol.
The main limitations of the study were its retrospective design and the small simple size, nevertheless, we consider the results a call for attention on asthma classification and the allocation of therapeutic resources.

Our results indicate that this schedule of omalizumab in severe asthmatic patients with a complex profile of sensitization to olive pollen may lead to better control of asthma and therefore, could represent a successful alternative therapy for these patients. However, more studies to validate this proof of concept are needed.

Acknowledgments

The authors thank to Carmen Galan to provide us data of pollen concentration for each year of the study.

Financial statement

All authors declare no financial disclosure in relationship with this paper that has been supported with an unrestricted grant from Menarini.

The authors have no conflicts of interest to declare.
REFERENCES


http://linkinghub.elsevier.com/retrieve/pii/S132389301530993X
TABLE

Table. Asthma control synthetic index (ACSI) based on the GEMA gradation and severity variables before and after receiving omalizumab pre-intraseasonally.

<table>
<thead>
<tr>
<th></th>
<th>ACSI</th>
<th>n (%)</th>
<th>McNemar</th>
<th>OCS</th>
<th>McNemar</th>
<th>Emergency</th>
<th>McNemar</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Before omalizumab (2011)</strong></td>
<td>2</td>
<td>0</td>
<td>McNemar</td>
<td>10</td>
<td>McNemar</td>
<td>12</td>
<td>McNemar</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>11 (33.3%)</td>
<td>McNemar</td>
<td>10 (30.3%)</td>
<td>McNemar</td>
<td>12 (36.3%)</td>
<td>McNemar</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>22 (66.7%)</td>
<td>McNemar</td>
<td>0</td>
<td>McNemar</td>
<td>0 (21.2%)</td>
<td>McNemar</td>
</tr>
<tr>
<td><strong>After omalizumab (2013)</strong></td>
<td>2</td>
<td>12 (36.4%)</td>
<td>McNemar</td>
<td>21</td>
<td>McNemar</td>
<td>16.2</td>
<td>McNemar</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>14 (42.4%)</td>
<td>McNemar</td>
<td>7.777 (p&lt;0.001)</td>
<td>McNemar</td>
<td>5 (15.1%)</td>
<td>McNemar</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>7 (21.2%)</td>
<td>McNemar</td>
<td>0.88 (p=0.345)</td>
<td>McNemar</td>
<td>2 (6%)</td>
<td>McNemar</td>
</tr>
</tbody>
</table>

n, number of patients; OCS, oral corticosteroids